AbCellera Biologics (AbCellera Biologics) Days Sales Outstanding : 338.18 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is AbCellera Biologics Days Sales Outstanding?

AbCellera Biologics's average Accounts Receivable for the three months ended in Dec. 2023 was $34.02 Mil. AbCellera Biologics's Revenue for the three months ended in Dec. 2023 was $9.18 Mil. Hence, AbCellera Biologics's Days Sales Outstanding for the three months ended in Dec. 2023 was 338.18.

The historical rank and industry rank for AbCellera Biologics's Days Sales Outstanding or its related term are showing as below:

ABCL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 24.63 Med: 121.73 Max: 332.04
Current: 330.79

During the past 6 years, AbCellera Biologics's highest Days Sales Outstanding was 332.04. The lowest was 24.63. And the median was 121.73.

ABCL's Days Sales Outstanding is ranked worse than
89.2% of 889 companies
in the Biotechnology industry
Industry Median: 71.83 vs ABCL: 330.79

AbCellera Biologics's Days Sales Outstanding increased from Dec. 2022 (306.12) to Dec. 2023 (338.18).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

AbCellera Biologics Days Sales Outstanding Historical Data

The historical data trend for AbCellera Biologics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Days Sales Outstanding Chart

AbCellera Biologics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

42.75

168.57

181.82

74.88

332.04

AbCellera Biologics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial														306.12	219.28	298.00	574.71	338.18

Competitive Comparison of AbCellera Biologics's Days Sales Outstanding

For the Biotechnology subindustry, AbCellera Biologics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AbCellera Biologics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's Days Sales Outstanding falls into.

AbCellera Biologics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

AbCellera Biologics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (38.593	+	30.59)	/	2 )	/	38.025	*	365
=	34.5915					/	38.025	*	365
=	332.04

AbCellera Biologics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (37.446	+	30.59)	/	2 )	/	9.179	*	365 / 4
=	34.018					/	9.179	*	365 / 4
=	338.18

AbCellera Biologics (NAS:ABCL) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

AbCellera Biologics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

AbCellera Biologics (AbCellera Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (NAS:ABCL) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

8QQ:Germany

Address

2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1

Website

https://www.abcellera.com

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Executives

John S. Montalbano	director	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Michael R Hayden	director	C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Veronique Lecault	director, officer: Chief Operating Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Thermopylae Holdings Ltd.	10 percent owner	2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Booth	officer: Chief Financial Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Lo	director	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
John Hamer	director, 10 percent owner	PO BOX 14528, RESEARCH TRIANGLE PARK NC 27709-4528
Ester Falconer	officer: Chief Technology Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Hansen Carl L. G.	director, 10 percent owner, officer: Chief Executive Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Tryn Stimart	officer: Chief Legal Officer	C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Peter Thiel	director	9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Dcvc Bio, L.p.	10 percent owner	317 UNIVERSITY AVENUE, SUITE 200, PALO ALTO CA 94301
Dcvc Bio Gp, Llc	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Zachary Bogue	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Matthew Ocko	10 percent owner	270 UNIVERSITY AVENUE, PALO ALTO CA 94301